NBIX Stock Analysis: Buy, Sell, or Hold?
NBIX - Neurocrine Biosciences Inc
$167.12
5.68 (3.52%)
▲
5d:
+6.84%
30d:
+6.65%
90d:
+30.71%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When NBIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NBIX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: NBIX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$319.04
Based on 13.0% avg growth
INTRINSIC VALUE TODAY
$198.10
15.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NBIX is currently trading at $167.12, which is considered fair relative to its 30-day fair value range of $155.00 to $162.64. The stock's valuation (Forward PE: 12.7) is in line with its historical norms (13.8). Remarkably, the market is currently pricing in an annual earnings decline of 2.6% over the next few years. This pessimistic expectation contrasts with the company's recent 2310.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NBIX is in a strong uptrend. The price is approaching resistance at $169.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $194.38 (+20.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NBIX is in a strong uptrend. The price is approaching resistance at $169.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $194.38 (+20.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$155.00 -
$162.64
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 20.4% below Wall St target ($194.38)
Trading Range Analysis
30-Day Trading Range
$155.00 -
$162.64
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$155.30
Resistance Level
$169.39
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.74
Wall Street Target
$194.38
(+20.4%)
Revenue Growth (YoY)
42.2%
Earnings Growth (YoY)
2310.5%
Profit Margin
21.6%
Valuation Discount vs History
-2.6% cheaper
PE vs Historical
12.7 vs 13.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.6%
(market-implied from PE analysis)
1-Year Target
$157.24
(-3%)
2-Year Target
$153.15
(-5%)
3-Year Target
$149.17
(-8%)
3-Yr Target (if PE normalizes)
(PE: 13→14)
$161.62
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 21.9%)
$500.56
(+210%)
Base:
(SPY PE: 12.7, Growth: 21.9%)
$292.72
(+81%)
Bear:
(PE: 10.8, Growth: 21.9%)
$248.81
(+54%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 24.90 | Current EPS (TTM): $6.49
Bull Case
$347.21
(+115%)
Analyst growth 95.3%, PE expands to 27.4
Base Case
$315.65
(+96%)
Market implied 95.3%, PE stable at 24.9
Bear Case
$109.90
(-32%)
Severe decline -20.0%, PE contracts to 21.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.7 to 13.8
Stabilization Target:
$174.92
(+8.3%)
PE Expansion Potential:
+8.3%
Share & Embed Analysis
Last updated: June 24, 2026 2:32 PM ET
Data refreshes hourly during market hours. Next update: 3:32 PM
Data refreshes hourly during market hours. Next update: 3:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kyle Gano
SELL
36400 shares
2026-01-16
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 63 BUY |
Advanced NBIX Option Strategies
Professional options setups generated by AI based on today's NBIX price and gamma walls.
